Clinical Correlation Between WISP2 and β-Catenin in Gastric Cancer.
pubmed: wnt1 2017-07-26
Summary:
Clinical Correlation Between WISP2 and β-Catenin in Gastric Cancer.
Anticancer Res. 2017 Aug;37(8):4469-4473
Authors: Li L, Cui Y, Ji JF, Jiang WG
Abstract BACKGROUND: Evidence indicates that wingless-type MMTV integration site family, member 1 (WNT1)-inducible signaling pathway protein 2 (WISP2) may play an important role in the development of gastric cancer (GC) by regulating the WNT/β-catenin signaling pathway. In the present study, we investigated whether there is correlation between WISP2 and β-catenin proteins, and their association with clinicopathological features in GC. MATERIALS AND METHODS: Immunohistochemical staining was carried out on 119 paraffin-embedded gastric cancer tissues and 99 adjacent normal gastric tissues collected from patients with GC at the Beijing Cancer Hospital. Data were analyzed by Spearman rank correlation and Chi-square tests. RESULTS: Both WISP2 and β-catenin were more highly expressed in GC tissues compared to adjacent normal tissues. Moreover, Spearman rank correlation analysis showed positive correlation between WISP2 and β-catenin (R=0.2254, p=0.0137). Additionally, their co-expression was seen in a higher proportion of patients with GC at early stage or without metastasis. CONCLUSION: These findings suggest that the expression of WISP2 and β-catenin might be a favorable biomarker for prediction and prognosis in the early stage of GC.
PMID: 28739741 [PubMed - in process]